NXGL NEXGEL INC

NEXGEL Reports Record Third Quarter 2024 Revenue of $2.94 Million, an Increase of 141% Year-Over-Year and 104% Sequentially

NEXGEL Reports Record Third Quarter 2024 Revenue of $2.94 Million, an Increase of 141% Year-Over-Year and 104% Sequentially

Quarterly revenue growth driven by a sequential increase of 99% in branded consumer products and 103% in contract manufacturing

Gross profit margin for the quarter was 43.6% compared to 28.2% in Q3 of 2023 and 28.5% in Q2 of 2024

LANGHORNE, Pa., Nov. 13, 2024 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced record third quarter revenue of $2.94 million, an increase of 141% year-over-year and 104% sequentially.

Third Quarter 2024 Financial Highlights:

  • Net Revenue was $2.94 million, compared to $1.22 million in Q3 2023 and $1.44 million in Q2 2024.
  • Gross Profit Margin was 43.6%, compared to 28.2% in Q3 2023 and 28.5% in Q2 2024.
  • Net loss was $754,000, compared to $552,000 in Q3 2023 and $979,000 in Q2 2024.
  • Adjusted EBITDA1 loss, a non-GAAP financial measure, was $347,000 in Q3 2024, compared to $464,000 in Q3 2023 and $788,000 in Q2 2024.
  • Cash as of September 30, 2024, was $1.10 million. Subsequent to the end of the quarter, the Company closed on a registered direct offering for gross proceeds of $2 million.

“The third quarter was yet another record quarter for the Company across all our key financial measures. Revenue increased 141% year-over-year and 104% sequentially, while gross margins were 43.6% and our Non-GAAP EBITDA loss improved to $347,000. Our significant growth was driven by approximately 100% sequential growth in both branded consumer products and contract manufacturing,” Adam Levy, NEXGEL’s Chief Executive Officer, commented. “As we head into the holiday season, we expect our year-over-year and sequential revenue growth to continue in the fourth quarter and our quarterly Non-GAAP EBITDA loss to narrow even further. Additionally, in the fourth quarter, our first orders of SilverSeal® to Cintas will occur. To meet the high demand we are seeing, subsequent to the third quarter, we strengthened our balance sheet with the closing of $2 million in gross proceeds from a registered direct offering.”

Third Quarter 2024 Financial Highlights

For the third quarter 2024, revenue totaled $2.94 million, an increase of 141%, as compared to the third quarter 2023, and an increase of 104%, as compared to the second quarter 2024. The increase year-over-year and sequentially in overall revenues was primarily due to sales growth in branded consumer products and contract manufacturing.

Gross profit totaled $1.3 million for the third quarter 2024, compared to a gross profit of $344,000 for the third quarter 2023 and gross profit of $410,000 for the second quarter 2024. The increase of $956,000 in gross profit year-over-year was primarily due to the increase in branded consumer products. The increase of $890,000 in gross profit sequentially was primarily due to the increase in branded consumer products and contract manufacturing.

Gross profit margin for the third quarter of 2024 was 43.6% compared to a gross margin for the third quarter of 2023 of 28.2% and a gross profit margin of 28.5% for the second quarter of 2024.

Cost of revenues increased by $781,000, or 89.1%, to $1.66 million for the third quarter 2024, as compared to $877,000 for the third quarter 2023. The increase in cost of revenues is primarily aligned with sales of branded consumer products, as both Silly George and Kenkoderm were acquired after the comparable 2023 period.

Selling, general and administrative expenses increased by $1.12 million, or approximately 118%, to $2.1 million for the third quarter 2024, as compared to $950,000 for the third quarter 2023. The increase in Selling, general and administrative expenses is primarily attributable to advertising, marketing, and Amazon fees, which increased $819,000.

Adjusted EBITDA1 loss, a non-GAAP financial measure, was approximately $347,000 as compared to an adjusted EBITDA loss of $464,000 for the third quarter of 2023 and $788,000 for the second quarter of 2024.

Net loss for the third quarter 2024 was $754,000 as compared to a net loss of $552,000 for the third quarter 2023, and a net loss of $979,000 for the second quarter 2024.

As of September 30, 2024, the Company had a cash balance of approximately $1.1 million. Subsequent to the end of the quarter, the Company closed on a registered direct offering of $2 million. The use of proceeds for the financing is for working capital and the immediate requirement for additional inventory and marketing to meet the higher-than-expected demand for the Silly George brand products.

As of November 13, 2024, NEXGEL had 6,790,777 shares of common stock outstanding, which number does not include the 727,272 shares of common stock we anticipate issuing in connection with our recent offering.

1. Adjusted EBITDA is a non-GAAP measure described in the section titled Non-GAAP Financial Measures” below and reconciled to the most directly comparable GAAP measure at the end of this release.

Third Quarter 2024 Financial Results Conference Call

Date: November 13, 2024

Time: 4:30 P.M. ET

Live Call: 1-800-225-9448 (U.S. Toll Free) or 1-203-518-9708 (International)

Webcast:

For interested individuals unable to join the conference call, a replay will be available through August 28, 2024, by dialing 1 (U.S. Toll Free) or 1-412-317-6671 (International). Participants must use the following code to access the replay of the call: 11157563. An archived version of the webcast will also be available for 90 days.

About NEXGEL, INC.

NEXGEL is a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogels. Based in Langhorne, Pa., the Company has developed and manufactured electron-beam, cross-linked hydrogels for over two decades. NEXGEL brands include SilverSeal®, Hexagels®, Turfguard®, Kenkoderm® and Silly George®. Additionally, NEXGEL has strategic contract manufacturing relationships with leading consumer healthcare companies.

Non-GAAP Financial Measures

Certain Non-GAAP financial measures are included in this press release. In the calculation of these measures, the Company excludes certain items, such as amortization of intangible assets, stock-based compensation, tax impact of adjustments, other unusual items and discrete items impacting income tax expense. The Company believes that excluding such items provides investors and management with a representation of the Company's core operating performance and with information useful in assessing its prospects for the future and underlying trends in the Company's operating expenditures and continuing operations. Management uses such Non-GAAP measures to evaluate financial results and manage operations. The release and the attachments to this release provide a reconciliation of each of the Non-GAAP measures referred to in this release to the most directly comparable GAAP measure. The Non-GAAP financial measures are not meant to be considered a substitute for the corresponding GAAP financial statements and investors should evaluate them carefully. These Non-GAAP financial measures may differ materially from the Non-GAAP financial measures used by other companies.

Forward-Looking Statement

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) (which Sections were adopted as part of the Private Securities Litigation Reform Act of 1995). Statements preceded by, followed by or that otherwise include the words “believe,” “anticipate,” “estimate,” “expect,” “intend,” “plan,” “project,” “prospects,” “outlook,” and similar words or expressions, or future or conditional verbs, such as “will,” “should,” “would,” “may,” and “could,” are generally forward-looking in nature and not historical facts, including, without limitation, our expectation that our year-over-year and sequential revenue growth will continue in the fourth quarter and our quarterly Non-GAAP EBITDA* loss will narrow even further as we head into the holidays.. These forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the Company's actual results, performance, or achievements to be materially different from any anticipated results, performance, or achievements for many reasons. The Company disclaims any intention to, and undertakes no obligation to, revise any forward-looking statements, whether as a result of new information, a future event, or otherwise. For additional risks and uncertainties that could impact the Company's forward-looking statements, please see the Company's Annual Report on Form 10-K for the year ended December 31, 2023, including but not limited to the discussion under “Risk Factors” therein, which the Company filed with the SEC and which may be viewed at /.

Investor Contacts:

Valter Pinto, Managing Director

KCSA Strategic Communications

212.896.1254

NEXGEL, INC

CONDENSED CONSOLIDATED BALANCE SHEETS

AS OF SEPTEMBER 30, 2024 AND DECEMBER 31, 2023

(Unaudited)

(in thousands, except share and per share data)

  September 30, 2024  December 31, 2023 
ASSETS:        
Current Assets:        
Cash and cash equivalents $1,059  $2,700 
Accounts receivable, net  894   633 
Inventory  1,778   1,319 
Prepaid expenses and other current assets  879   400 
Total current assets  4,610   5,052 
Goodwill  1,124   1,128 
Intangibles, net  839   326 
Property and equipment, net  2,219   1,499 
Operating lease - right of use asset  1,685   1,855 
Other assets  95   95 
Total assets $10,572  $9,955 
         
LIABILITIES AND STOCKHOLDERS’ EQUITY        
Current Liabilities:        
Accounts payable $1,505  $1,233 
Accrued expenses and other current liabilities  609   398 
Deferred revenue  179   20 
Current portion of note payable  83   80 
Warrant liability  109   146 
Contingent consideration liability  271   439 
Financing lease liability, current portion  58   - 
Operating lease liabilities, current portion  234   233 
Total current liabilities  3,048   2,549 
Operating lease liabilities, net of current portion  1,589   1,727 
Financing lease liability, net of current portion  323   - 
Notes payable, net of current portion  626   513 
Total liabilities  5,586   4,789 
         
Commitments and Contingencies (Note 16)        
         
Preferred stock, par value $0.001 per share, 5,000,000 shares authorized, no shares issued and outstanding  -   - 
Common stock, par value $0.001 per share, 25,000,000 shares authorized; 6,790,777 and 5,741,838 shares issued and outstanding as of September 30, 2024 and December 31, 2023, respectively  7   6 
Additional paid-in capital  21,826   19,406 
Accumulated deficit  (17,146)  (14,715)
Total NexGel stockholders’ equity  4,687   4,697 
Non-controlling interest in joint venture  299   469 
Total stockholders’ equity  4,986   5,166 
Total liabilities and stockholders’ equity $10,572  $9,955 



NEXGEL, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2024 AND 2023

(Unaudited)

(in thousands, except share and per share data)

             
  Three Months Ended  Nine Months Ended 
  September 30,  September 30, 
  2024  2023  2024  2023 
Revenues, net $2,940  $1,221  $5,647  $3,007 
                 
Cost of revenues  1,658   877   3,678   2,546 
                 
Gross profit  1,282   344   1,969   461 
                 
Operating expenses                
Research and development  -   6   78   90 
Selling, general and administrative  2,070   950   4,604   2,629 
Total operating expenses  2,070   956   4,682   2,719 
                 
Loss from operations  (788)  (612)  (2,713)  (2,258)
                 
Other income (expense)                
Interest expense  (20)  (3)  (67)  (13)
Interest income  -   1   2   3 
Other income  39   -   40   3 
Gain on investments  5   44   62   168 
Changes in fair value of warrant liability  10   18   37   96 
Total other income, net  34   60   74   257 
Loss before income taxes  (754)  (552)  (2,639)  (2,001)
Income tax expense  -   -   -   - 
Net loss $(754) $(552) $(2,639) $(2,001)
Less: Loss (income) attributable to non-controlling interest in joint venture  61   2   208   (58)
Net loss attributable to NexGel stockholders  (693)  (550)  (2,431)  (2,059)
Net loss per common share - basic $(0.11) $(0.10) $(0.39) $(0.36)
Net loss per common share - diluted $(0.11) $(0.10) $(0.39) $(0.36)
Weighted average shares used in computing net loss per common share - basic  6,569,403   5,714,316   6,274,221   5,654,981 
Weighted average shares used in computing net loss per common share – diluted  6,569,403   5,714,316   6,274,221   5,654,981 



NEXGEL, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2024 AND 2023

(Unaudited)

(in thousands)

       
  Nine Months Ended

September 30,
 
  2024  2023 
Operating Activities        
Net loss $(2,431) $(2,059)
Adjustments to reconcile net loss to net cash used in operating activities:        
Income (loss) attributable to non-controlling interest in joint venture  (208)  58 
Depreciation and amortization  328   103 
Changes in ROU asset and operating lease liability  31   33 
Share-based compensation and restricted stock vesting  271   120 
Gain on investment in marketable securities  (62)  168 
Changes in fair value of warrant liability  (37)  (96)
         
Changes in operating assets and liabilities:        
Accounts receivable  (261)  (936)
Inventory  (459)  (588)
Prepaid expenses and other assets  (479)  (227)
Accounts payable  272   808 
Accrued expenses and other current liabilities  (132)  (67)
Deferred revenue  159   34 
Net Cash Used in Operating Activities  (3,008)  (2,649)
         
Investing Activities        
Proceeds from sales of marketable securities  62   5,340 
Capital expenditures  (374)  (611)
Net cash paid for Asset acquisition  (400)  - 
Net Cash (Used in) Provided by Investing Activities  (712)  4,729 
         
Financing Activities        
Proceeds from margin line of credit  345   89 
Proceeds from Rights offering  1,950    
Investment by joint venture partner  37     
Principal payment on financing lease liability  (36)   
Change in contingent consideration liability  (164)   
Principal payments of notes payable  (53)  (4)
Net Cash Provided by Financing Activities  2,079   85 
Net Decrease in Cash  (1,641)  2,165 
Cash – Beginning of period  2,700   1,101 
Cash – End of period $1,059  $3,266 
Supplemental Disclosure of Cash Flows Information        
Cash paid during the year for:        
Interest $65  $7 
Taxes $  $ 
         
Supplemental Non-cash Investing and Financing activities        
Shares issued in conjunction with asset acquisition $200  $ 
Property and equipment financed under notes payable $165  $ 
Property and equipment financed under financing leases $416  $ 
Property and equipment contributed as capital investment to JV $  $500 
ROU asset and operating lease liabilities recognized upon consolidation of JV $  $334 



RECONCILIATION OF SELECTED GAAP MEASURES TO NON-GAAP MEASURES

(in thousands, except per share amounts)

CALCULATION OF EBITDA & ADJUSTED EBITDA

  Three Months Ended June 30, 







Three Months Ended September 30,
  2024  2024   2023 
Net (loss) income: $(979) $(754)  $(552)
Less: Loss (income) attributable to non-controlling interest in joint venture  94   61    2 
Net loss attributable to NexGel stockholders  (885)  (693)   (550)
Adjustments:          
Depreciation and amortization  82   184    35 
Interest expense  30   20    3 
Income tax expense  -   -    - 
EBITDA  (773)  (489)   (512)
Change in warrant liability(1)  (79)  (11)   (19)
Share-based compensation expense(2)  64   153    67 
Adjusted EBITDA: $(788) $(347)  $(464)



  Nine Months Ended September 30, 
  2024   2023  
Net (loss) income: $(2,639 ) $(2,001) 
Less: Loss (income) attributable to non-controlling interest in joint venture  208    (58) 
Net loss attributable to NexGel stockholders  (2,431)   (2,059) 
Adjustments:        
Depreciation and amortization  328    103  
Interest expense, net  65    10  
Income tax expense  -    -  
EBITDA  (2,038)   (1,946) 
Change in warrant liability (1)  (37)   (96) 
Share-based compensation expense(2)  271    120  
Adjusted EBITDA: $(1,804)  $(1,922) 



 (1)This adjustment gives effect to non-cash warrant liability changes incurred during the periods.
   
 (2)The adjustments represent share-based compensation expense related to awards of stock options, restricted stock units, or common stock in exchange for services. Although we expect to continue to award stock in exchange for services, the amount of non-cash stock-based compensation is excluded as it is subject to change as a result of one-time or non-recurring projects.


EN
13/11/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on NEXGEL INC

 PRESS RELEASE

NEXGEL to Participate in the iAccess Alpha Virtual Best Ideas Winter C...

NEXGEL to Participate in the iAccess Alpha Virtual Best Ideas Winter Conference on December 10-11, 2024 LANGHORNE, Pa., Nov. 21, 2024 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of medical and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogels for healthcare and consumer applications, today announced that Adam Levy, Chief Executive Officer, will present at the iAccess Alpha Virtual Best Ideas Winter Conference 2024 on December 10 and 11, 2024. iAccess Alpha Virtual Conference Details:Date: December 10...

 PRESS RELEASE

NEXGEL Reports Record Third Quarter 2024 Revenue of $2.94 Million, an ...

NEXGEL Reports Record Third Quarter 2024 Revenue of $2.94 Million, an Increase of 141% Year-Over-Year and 104% Sequentially Quarterly revenue growth driven by a sequential increase of 99% in branded consumer products and 103% in contract manufacturing Gross profit margin for the quarter was 43.6% compared to 28.2% in Q3 of 2023 and 28.5% in Q2 of 2024 LANGHORNE, Pa., Nov. 13, 2024 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announce...

 PRESS RELEASE

NEXGEL Announces $2,000,000 Registered Direct Offering

NEXGEL Announces $2,000,000 Registered Direct Offering LANGHORNE, Pa., Nov. 11, 2024 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: NXGL), a leading provider of medical and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogels for healthcare and consumer applications, today announced it has entered into definitive agreements for the issuance and sale of an aggregate of 727,272 of its shares of common stock and the issuance of warrants to purchase up to an aggregate of 363,636 shares of common stock for a combined offering purchase pric...

 PRESS RELEASE

NEXGEL to Report Third Quarter 2024 Financial Results on November 13th

NEXGEL to Report Third Quarter 2024 Financial Results on November 13th Management will host a conference call at 4:30 P.M. ET on the same day LANGHORNE, Pa., Nov. 11, 2024 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced it will report its financial results for the third quarter 2024, after the market close on November 13, 2024. Following the release of its financial results, the Company will host a conference call at 4:30 P.M. E...

 PRESS RELEASE

NEXGEL to Participate in Upcoming October Investor Conferences

NEXGEL to Participate in Upcoming October Investor Conferences LANGHORNE, Pa., Oct. 11, 2024 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of medical and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogels for healthcare and consumer applications, today announced that Adam Levy, Chief Executive Officer, is scheduled to participate in the following October 2024 investor conferences. Maxim’s Healthcare Virtual SummitDate: October 15-17, 2024Presentation Format: Fireside Chat with Naz Rahman, Vice Preside...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch